Oncotarget is a highly reputable oncology journal online publisher founded by two eminent researchers. The chief editors are Mikhail Blagosklonny and Andrei V. Gudkov. The duo set up the peer-to-peer journal in 2010 with the intentions of speeding up the medical research process. In the past, scientists had to painstakingly wade their way through the mud to get published and reviewed by their academic peers. Those days, it was commonplace to find famous researchers, unknowingly, wasting valuable years and money researching on an aspect that had already been found elsewhere. Oncortaget sought to avoid such costly conundrums with their real-time online publishing journal.
Scholars jumped on the Oncotarget bandwagon in droves. This journal publishes on cancer research but has recently expanded to accommodate other medical fields’ journals. According to the expert reviews posted here, the journal’s receivership peaked in 2013 heading into 2014. The number of external citations per document had risen steadily in the last two years. The external citations per journal at Oncotarget has shot from below 5,000 to 20,000 since 2014.Effectively, and, as anticipated, Oncotarget succeeds in bringing together scholars from all parts of the world. There were increased collaborations among internationally based peers working on the same problem sets, according to the trusted journal rating website.
U.S-based authors and researchers have a record of well over a million medical journals published on Oncotarget in the last five years. Chinese scholars and scientists racked up a tally of almost half a million oncology journals at the site.Finding research data and statistics on Oncotarget is a straightforward, well-outlined process. The author has to be familiar with the indexing style accepted by Mikhail Blagosklonny and Andrei V. Gudkov at their resource portal. It is essential you, as the prospective medical author, get to read the open source agreement, in-depth, before publishing at Oncortaget. That helps to avoid any misunderstandings between you and the editors at this Medicus/MEDLINE/PublMed indexed award-winning scientific journal.
Oncology is a medicinal branch that primary deals with the diagnosis, prevention and also treating a life-threatening disease. The oncologist is a medical practitioner who practices oncology. The etymological origin of the name Oncology is the Greek word which refers to as tumor, mass or volume. The three primary mechanisms that would include an individual who is suffering from such life-threatening disease are prevention, early finding and proper treatment. Prevention can do by limiting or stopping a habit that is to add smoke and tobacco to your body.
Cancers usually managed with a different discussion about global conferences or discussion where medical, surgical, radiation oncologist along with the radiologist and pathologist meet to find the best potential medical procedure for getting recovery from such illness. And this is where Mikhail Blagosklonny steps in with his years of experiences and skills as a scientist who is studying cancer and aging to help the individual from a different field. He is also teaching oncology at a Cancer Institute under the name of the Roswell Park in New York. Visit ResearchGate to keep up to date with Mikhail’s latest work.
Blagosklonny after taking his formal higher education from one of the very renowned and competent universities known as First Medical University in Pavlov State that produced many famous names for the field of oncology. He has completely Doctorate in cardiology and experimental medicine
He, in 2002 got appointed as professor in one of the most notable medical institute of all time and with the help of his teaching skills he helped his institute to earn international recognition and fame. He started his professional with them as an associate professor, but gradually he became one of the crucial members of the University who has invested a huge part of his life for turning this ordinary institute into one of the famous medical institutes in the whole country.
Mihail Blagosklonny took the most complicated topic for his research. He knew that those sectors are hard, but he knew that if he can able to do something in such field, then people will remember for years. The fields that he chose for his research includes include targeted therapies for life-threatening diseases which can only affect the damaged cell and leave the healthy cell intact. Follow Mikhail on Google Scholar
Mikhail Blagosklonny is a world class scientist who is internationally famous for his research on aging and cancer. He works at Roswell Park Cancer Institute, New York as professor of oncology. This institute is the oldest cancer treatment and research facility in the United States. Mikhail Blagosklonny was born in Russia. He went to First Pavlov State Medical University in St. Peterburg to become a doctor. From there, he acquired an M.D. degree in internal medicine and Ph.D. degree in cardiology and experimental medicine.
In 2002, Blagosklonny joined New York Medical College in Valhalla, New York as an associate professor of medicine. Later, he joined Ordway Research Institute in Albany, New York as a senior scientist. In 2009, Blagosklonny joined Roswell Park Cancer Institute as professor of oncology on researchgate.net. His prime area of interest in research has always been cancer. He has worked a lot on targeted cancer therapies that avoid damage to normal cells. His other area of interest in research is aging.
Mikhail Blagosklonny has proposed using rapamycin for increasing human life. Rapamycin is a popular drug which is used for treating cancer. In the world of medicine science, Blagosklonny is known as a strong advocate for rapamycin who believes it results in longevity. As a result, he has formulated a hypothesis which states the role of TOR signaling in cancer and aging.
Blagosklonny also works with popular medical science journals. He is editor-in-chief of three journals: Oncotarget, Cell cycle, and Aging. In addition to this, he is also an associate editor of popular medicine science journal Cancer Biology & Therapy. Mikhail Blagosklonny is an editorial board member of Cell Death & Differentiation, Autophagy, Am J Pathology, International J Cancer, and PLOS ONE. He is also the founder of Cell Cycle on tandfonline.com. In peer-reviewed journals, Blagosklonny has authored more than 270 articles.
There is no successful person in the world that has not faced criticism. This is also true for Professor Blagosklonny. He has been criticized by fellow scientists in different ways. One of them criticized the reviewing process of Oncotarget whose editor-in-chief is Blagosklonny. He alleged that Mikhail Blagosklonny encourages authors to include references to his publications in their articles. As a result, Mikhail Blagosklonny’s personal impact factor increases to a great level.